MacroGenics restates pro forma to treat CDMO sale as discontinued ops; net cash $110.8M

MACROGENICS INC

CDMO sale to Bora closed 6/30/26; gross proceeds $122.5M, net cash $110.8M after $8.8M costs; up to $5M contingent.
Pro forma continuing ops net loss: Q1'26 $41.3M vs $36.8M hist; FY25 $91.2M vs $74.6M; FY24 $68.6M vs $67.0M; FY23 $11.3M vs $9.1M.
CDMO revenue eliminated from continuing ops: Q1'26 $14.1M, FY25 $52.6M, FY24 $13.1M, FY23 $9.8M.
Company now focuses on R&D pipeline; CDMO results reported as discontinued operations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.